How to buy Zoetis stock

Zoetis Inc is a drug manufacturers-specialty & generic business based in the US. Zoetis shares (ZTS) are listed on the NYSE and all prices are listed in US Dollars. Zoetis employs 10,600 staff and has a trailing 12-month revenue of around USD$6.7 billion.

How to buy shares in Zoetis

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Zoetis. Find the stock by name or ticker symbol: ZTS. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Zoetis reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Zoetis, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Zoetis. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Zoetis share price

Use our graph to track the performance of ZTS stocks over time.

Zoetis shares at a glance

• Key figures

Information last updated 2021-02-24.

52-week range	USD$89.6171 - USD$176.3666
50-day moving average	USD$161.9767
200-day moving average	USD$161.6499
Wall St. target price	USD$188.14
PE ratio	46.6433
Dividend yield	USD$0.8 (0.5%)
Earnings per share (TTM)	USD$3.42

Buy Zoetis shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Zoetis stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Zoetis Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Zoetis financials

Revenue TTM	USD$6.7 billion
Operating margin TTM	34.47%
Gross profit TTM	USD$4.6 billion
Return on assets TTM	11.43%
Return on equity TTM	50.49%
Profit margin	24.54%
Book value	$7.929
Market capitalisation	USD$75.8 billion

TTM: trailing 12 months

Shorting Zoetis shares

There are currently 3.7 million Zoetis shares held short by investors – that's known as Zoetis's "short interest". This figure is 21.8% up from 3.0 million last month.

There are a few different ways that this level of interest in shorting Zoetis shares can be evaluated.

Zoetis's "short interest ratio" (SIR)

Zoetis's "short interest ratio" (SIR) is the quantity of Zoetis shares currently shorted divided by the average quantity of Zoetis shares traded daily (recently around 1.7 million). Zoetis's SIR currently stands at 2.15. In other words for every 100,000 Zoetis shares traded daily on the market, roughly 2150 shares are currently held short.

However Zoetis's short interest can also be evaluated against the total number of Zoetis shares, or, against the total number of tradable Zoetis shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Zoetis's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Zoetis shares in existence, roughly 10 shares are currently held short) or 0.0078% of the tradable shares (for every 100,000 tradable Zoetis shares, roughly 8 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Zoetis.

Find out more about how you can short Zoetis stock.

Zoetis's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Zoetis.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Zoetis's total ESG risk score

Total ESG risk: 28.6

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Zoetis's overall score of 28.6 (as at 01/01/2019) is nothing to write home about – landing it in it in the 49th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Zoetis is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Zoetis's environmental score

Environmental score: 2.72/100

Zoetis's environmental score of 2.72 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Zoetis is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Zoetis's social score

Social score: 13/100

Zoetis's social score of 13 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Zoetis is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Zoetis's governance score

Governance score: 8.87/100

Zoetis's governance score puts it squarely in the 1st percentile of companies rated in the same sector. That could suggest that Zoetis is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Zoetis's controversy score

Controversy score: 1/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Zoetis scored a 1 out of 5 for controversy – the highest score possible, reflecting that Zoetis has managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Zoetis Inc was last rated for ESG on: 2019-01-01.

Total ESG score	28.6
Total ESG percentile	49.38
Environmental score	2.72
Environmental score percentile	1
Social score	13
Social score percentile	1
Governance score	8.87
Governance score percentile	1
Level of controversy	1

Zoetis share price volatility

Over the last 12 months, Zoetis's shares have ranged in value from as little as $89.6171 up to $176.3666. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Zoetis's is 0.6371. This would suggest that Zoetis's shares are less volatile than average (for this exchange).

Zoetis overview

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites that include fleas, ticks, and worms. It also provides other pharmaceutical products, which comprise pain and sedation, antiemetic, reproductive, and oncology products; Dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives that offer medicines to livestock. In addition, the company offers portable blood and urine analysis systems, and point-of-care diagnostic products, including instruments and reagents, rapid immunoassay tests, reference laboratory kits, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision livestock farming. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.

Frequently asked questions

• What percentage of Zoetis is owned by insiders or institutions?

  Currently 0.081% of Zoetis shares are held by insiders and 94.212% by institutions.

• How many people work for Zoetis?

  Latest data suggests 10,600 work at Zoetis.

• When does the fiscal year end for Zoetis?

  Zoetis's fiscal year ends in December.

• Where is Zoetis based?

  Zoetis's address is: 10 Sylvan Way, Parsippany, NJ, United States, 07054

• What is Zoetis's ISIN number?

  Zoetis's international securities identification number is: US98978V1035

• What is Zoetis's CUSIP number?

  Zoetis's Committee on Uniform Securities Identification Procedures number is: 98978V103